多灶性肝细胞癌的基因组与转录异质性
研究对6例多灶性肝细胞癌患者的34个肿瘤和6份癌旁正常肝组织行全外显子组和RNA测序,并检测Ki67、AFP、P53、Survivin和CD8蛋白表达及FISH验证索拉非尼靶基因扩增。结果显示瘤间存在基因组与转录异质性,仅1/6例患者的索拉非尼靶向改变位于系统发育树主干;基于66个免疫标志物的聚类分析识别出低表达(7个结节)和高表达(11个结节)两个免疫亚群,CD8+ T细胞在高表达簇中更富集。
要点
- 6例多灶性肝细胞癌34个肿瘤的全外显子组和RNA测序揭示瘤间基因组与转录异质性。
- 仅1/6例患者的索拉非尼靶向改变位于系统发育树主干,或解释索拉非尼临床应答率相对低。
- RNA表达模式与Edmondson-Steiner分级相关,34个结节聚类为低表达(7个)和高表达(11个)免疫亚群。
核心结论
- 本研究提供多灶性肝细胞癌基因组与转录异质性、克隆演化和免疫浸润的详细视图。
- 可靶向改变和免疫景观的异质性可能有助于解释多灶性肝细胞癌患者对靶向药物和免疫治疗的临床应答。
研究设计与样本
- 对来自6例多灶性肝细胞癌患者的34个肿瘤和6份癌旁正常肝组织行全外显子组测序和RNA测序。
- 采用免疫组化检测Ki67、AFP、P53、Survivin和CD8蛋白表达。
- 采用荧光原位杂交验证索拉非尼靶基因的扩增状态。
主要发现
- 研究解析了每例多灶性肝细胞癌患者各肿瘤间的基因组和转录异质性,包括突变谱、拷贝数改变、肿瘤演化轨迹和肿瘤免疫微环境谱。
- 仅1/6例患者的索拉非尼靶向改变位于系统发育树主干。
- RNA表达模式与Edmondson-Steiner分级相关。
- 基于66个已报道免疫标志物的差异表达,对34个结节行无监督层次聚类分析识别出免疫亚群:低表达簇含7个结节,高表达簇含11个结节。
- CD8+ T细胞在高表达簇结节中更富集。
关键数值与推荐
- 索拉非尼靶向改变位于系统发育树主干的患者为1/6例。
- 免疫标志物聚类分析中低表达簇含7个结节,高表达簇含11个结节。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) often presents with multiple nodules within the liver, with limited effective interventions. The high genetic heterogeneity of HCC might be the major cause of treatment failure. We aimed to characterize genomic heterogeneity, infer clonal evolution, investigate RNA expression pattern and explore tumour immune microenvironment profile of multifocal HCC. PATIENTS AND METHODS: Whole-exome sequencing and RNA sequencing were carried out in 34 tumours and 6 adjacent normal liver tissue samples from 6 multifocal HCC patients. Protein expression of Ki67, AFP, P53, Survivin and CD8 was detected by immunohistochemistry. Fluorescence in situ hybridization was carried out to validate the amplification status of sorafenib-targeted genes. RESULTS: We deciphered genomic and transcriptional heterogeneity among tumours in each multifocal HCC patient including mutational profiles, copy number alterations, tumour evolutionary trajectory and tumour immune microenvironment profiles. Of note, sorafenib-targeted alterations were identified in the trunk of phylogenetic tree in only one out of the six patients, which may explain the relative low treatment response rate to sorafenib in clinical practice. Moreover, we demonstrated RNA expression patterns and tumour immune microenvironment profiles of all nodules. We found that RNA expression pattern was associated with Edmondson-Steiner grading. Based on the differential expression of 66 reported immune markers, unsupervised hierarchical clustering analysis of 34 nodules identified immune subsets: one low expression cluster with seven nodules and one high expression cluster with 11 nodules. CD8+ T cells were more enriched in nodules of the high expression cluster. CONCLUSIONS: Our study provided a detailed view of genomic and transcriptional heterogeneity, clonal evolution and immune infiltration of multifocal HCC. The heterogeneity of druggable targets and immune landscape might help interpret the clinical responsiveness to targeted drugs and immunotherapy for multifocal HCC patients.
引用
- Xu LX, He MH, Dai ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019. PMID: 30916311. doi:10.1093/annonc/mdz103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。